Some dietary supplements may help naturally boost GLP-1, but more research is needed to better understand their potential ...

Experts emphasized that obesity is a chronic, relapsing condition and lifelong therapy—in some form—will be necessary.

In a large U.S. retrospective cohort study published in JAMA Network Open, investigators report that glucagon-like peptide-1 ...

Abbott Healthcare has received a positive regulatory outcome after presenting the Active Post-Marketing Surveillance (PMS) ...

Incregen Therapeutics Advances First-in-Class GIP Ligand Antagonist INC-118 into IND-Enabling Development to Address Long-Term Obesity Management INC-118 directly antagonizes the circulating Glucose ...

A new study led by a researcher at University College London (UCL) suggests that the anti-obesity drug semaglutide may reduce ...

“Orforglipron and retatrutide from Eli Lilly exemplify the next generation of metabolic therapies: oral formulations that promise improved adherence, triple-hormone mechanisms that deliver superior ...

Winselow Tucker, president and general manager, Eli Lilly and Company (India) Pvt Ltd, addresses concerns regarding ...

Looking to overcome some of the limitations of existing obesity drugs, Alveus Therapeutics has debuted with nearly $160 ...

Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight ...

People prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and ...